BetterScholar BetterScholar

W. De Roock

Clinical Cancer Research, The Lancet Oncology, Journal of Clinical Oncology, Journal of the American Medical Association, BMC Cancer, Journal of Cancer Research and Clinical Oncology, Clinical colorectal cancer, Biomarkers Show more
12
Role
Title
Level Year L/R
🦁 Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
37 auth. W. De Roock, B. Claes, David Bernasconi, J. De Schutter, B. Biesmans, G. Fountzilas, K. Kalogeras, V. Kotoula, D. Papamichael, P. Laurent-Puig, F. Penault-Llorca, P. Rougier, B. Vincenzi, D. Santini, G. Tonini, ... F. Cappuzzo, M. Frattini, F. Molinari, P. Saletti, S. De Dosso, M. Martini, A. Bardelli, S. Siena, A. Sartore-Bianchi, J. Tabernero, T. Macarulla, F. Di Fioré, A. Gangloff, F. Ciardiello, P. Pfeiffer, C. Qvortrup, T. P. Hansen, E. Van Cutsem, H. Piessevaux, D. Lambrechts, M. Delorenzi, S. Tejpar 		10 2010
10
🦁
🦁 Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.
18 auth. W. De Roock, D. Jonker, F. Di Nicolantonio, A. Sartore-Bianchi, D. Tu, S. Siena, S. Lamba, S. Arena, M. Frattini, H. Piessevaux, ... E. Van Cutsem, C. O'Callaghan, S. Khambata-Ford, J. Zalcberg, J. Simes, C. Karapetis, A. Bardelli, S. Tejpar 		9 2010
9
🦁
🦁 KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.
W. De Roock, V. de Vriendt, N. Normanno, F. Ciardiello, S. Tejpar 		9 2011
9
🦁
🐜 Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab.
16 auth. B. Jacobs, W. De Roock, H. Piessevaux, R. Van Oirbeek, B. Biesmans, J. De Schutter, S. Fieuws, J. Vandesompele, M. Peeters, J. Van Laethem, ... Y. Humblet, F. Penault-Llorca, G. De Hertogh, P. Laurent-Puig, E. Van Cutsem, S. Tejpar 		8 2009
8
🐜
🐜 PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer
9 auth. H. Prenen, J. De Schutter, B. Jacobs, W. De Roock, B. Biesmans, B. Claes, ... D. Lambrechts, E. Van Cutsem, S. Tejpar 		8 2009
8
🐜
🐜 Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab: A Fluorescent In situ Hybridization Study
14 auth. N. Personeni, S. Fieuws, H. Piessevaux, G. De Hertogh, J. De Schutter, B. Biesmans, W. De Roock, An Capoen, M. Debiec-Rychter, J. Van Laethem, ... M. Peeters, Y. Humblet, E. Van Cutsem, S. Tejpar 		7 2008
7
🐜
🐜 Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes
21 auth. G. Pentheroudakis, V. Kotoula, W. De Roock, G. Kouvatseas, P. Papakostas, T. Makatsoris, D. Papamichael, I. Xanthakis, J. Sgouros, D. Televantou, ... G. Kafiri, A. Tsamandas, E. Razis, E. Galani, D. Bafaloukos, I. Efstratiou, I. Bompolaki, D. Pectasides, N. Pavlidis, S. Tejpar, G. Fountzilas 		6 2013
6
🐜
🐜 A let-7 microRNA-Binding Site Polymorphism in KRAS Predicts Improved Outcome in Patients with Metastatic Colorectal Cancer Treated with Salvage Cetuximab/Panitumumab Monotherapy
14 auth. Z. Saridaki, J. Weidhaas, H. Lenz, P. Laurent-Puig, B. Jacobs, J. De Schutter, W. De Roock, D. Salzman, Wu Zhang, Dongyun Yang, ... C. Pilati, O. Bouché, H. Piessevaux, S. Tejpar 		6 2014
6
🐜
🐜 The role of KRAS, BRAF, NRAS, and PIK3CA mutations as markers of resistance to cetuximab in chemorefractory metastatic colorectal cancer.
10 auth. D. Lambrechts, W. De Roock, H. Prenen, J. De Schutter, B. Jacobs, B. Biesmans, ... B. Claes, G. De Hertogh, E. van Cutsem, S. Tejpar 		5 2009
5
🐜
🐜 EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab
23 auth. E. Razis, G. Pentheroudakis, G. Rigakos, Mattheos Bobos, G. Kouvatseas, O. Tzaida, T. Makatsoris, P. Papakostas, M. Bai, A. Goussia, ... E. Samantas, D. Papamichael, Ourania Romanidou, I. Efstratiou, E. Tsolaki, A. Psyrri, W. De Roock, D. Bafaloukos, G. Klouvas, S. Tejpar, K. Kalogeras, D. Pectasides, G. Fountzilas 		5 2014
5
🐜
🐜 The prognostic role of ephrin A2 and endothelial growth factor receptor pathway mediators in patients with advanced colorectal cancer treated with cetuximab.
19 auth. A. Strimpakos, G. Pentheroudakis, V. Kotoula, W. De Roock, G. Kouvatseas, P. Papakostas, T. Makatsoris, D. Papamichael, A. Andreadou, J. Sgouros, ... A. Zizi-Sermpetzoglou, A. Kominea, D. Televantou, E. Razis, E. Galani, D. Pectasides, S. Tejpar, K. Syrigos, G. Fountzilas 		4 2013
4
🐜
🐜 DUSP 4 expression identifies a subset of colorectal cancer tumors that differ in MAPK activation, regardless of the genotype
14 auth. V. de Vriendt, W. De Roock, Antonio F Di Narzo, S. Tian, B. Biesmans, B. Jacobs, E. Budinská, X. Sagaert, S. Rossi, Giovanni D'Ario, ... M. Delorenzi, I. Simon, L. Vecchione, S. Tejpar 		4 2013
4
🐜